ALETA-002

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameALETA-002

Drug Alias NameALETA002ALETA-002

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionT lymphocyte replacementsAnti-HER2Anti-CD19 +[4]

TargetsReceptor protein-tyrosine kinase erbB-2B-lymphocyte antigen CD19Transforming growth factor beta

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAleta BioTherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAleta BioTherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A